Depakote (Valproate/Divalproex Sodium)

Depakote (Valproate/Divalproex Sodium) is FDA-approved to treat Bipolar I Disorder (acute manic episodes), absence seizures, focal seizures, and migraine prevention. It is also used off-label for Bipolar I and Bipolar II Disorder maintenance, alcohol withdrawal (as adjunct), and diabetic neuropathy.

Depakote (divalproex sodium) belongs to the mood stabilizer and anticonvulsant drug class. It is a chemical compound that releases valproic acid in the body after being absorbed. It is sometimes referred to as a mood stabilizer when used in psychiatric settings and as an anticonvulsant in neurology.

No. Depakote is not classified as an antipsychotic. It is a mood stabilizer and anticonvulsant. Unlike antipsychotics, which primarily target dopamine receptors, Depakote works through multiple mechanisms involving neurotransmitters and intracellular signaling to stabilize mood and reduce seizure activity. It may be used in combination with antipsychotics in some treatment plans for bipolar disorder.

Depakote (divalproex sodium) releases valproic acid in the body, which acts through multiple mechanisms to stabilize mood and reduce seizure activity. It is thought to increase levels of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter that reduces neuronal excitability. It also modulates sodium and calcium channels in neurons (brain cells), reducing abnormal electrical activity in the brain. These combined effects help prevent manic episodes in bipolar disorder and control seizure activity.

Common side effects of Depakote include nausea, vomiting, diarrhea, dizziness, drowsiness, tremor, hair loss (alopecia), weight gain, and blurred vision. Some individuals may experience liver function changes or pancreatitis, which require prompt medical attention. Contact your clinician if side effects are severe or persistent.

Yes. Weight gain is a commonly reported side effect of Depakote. Increased appetite, changes in metabolism, and fluid retention can contribute to weight changes. Not everyone experiences weight gain, and the degree varies between individuals. Speak with your clinician if weight changes are a concern—they can discuss strategies to help manage this side effect.

Yes. Drowsiness and fatigue are common side effects, particularly when starting treatment or when the dose is increased. For many individuals, tiredness improves as the body adjusts to the medication, or it can be managed through proper timing of doses. If you notice persistent or significant tiredness, speak with your clinician about the timing of your dose or alternative options.

Yes. Temporary hair loss (alopecia) is a reported side effect in some individuals. This is as a reversible side effect known as telogen effluvium (diffuse thinning), affecting up to 12% of users. It usually occurs within the first few months of treatment and is often dose-dependent. Hair loss is generally temporary, with regrowth often occurring upon reducing the dose or stopping the medication. Zinc and selenium supplementation has been suggested in some clinical discussions, but always consult your clinician before adding any supplements.

For acute manic episodes, some improvement may be noticeable within 1–2 weeks of starting Depakote. Full mood stabilization and maintenance benefits may take several weeks to months. Therapeutic effects are generally established once stable blood levels in the therapeutic range are reached, which your clinician will monitor. Regular follow-ups with your clinician are important to monitor your response and adjust your care plan as needed.

Depakote has a half-life of approximately 9–16 hours for the immediate-release form and somewhat longer for the extended-release (Depakote ER) formulation. It is generally cleared from the body within 2–4 days after stopping. However, individual factors such as liver function, age, and other medications can affect how quickly it is metabolized. Always follow your psychiatric provider’s directions on when to stop taking medications or change dosages.

No. Depakote (divalproex sodium) is not a controlled substance. It is a prescription-only medication that requires a clinician’s prescription to obtain, but it is not classified as a controlled substance by the DEA.

Depakote may affect sexual function in some individuals. Reported effects can include decreased libido and, in some cases, hormonal changes (such as elevated testosterone levels in women or reduced testosterone in men), which may affect sexual desire and function. If you notice changes in sexual function, let your clinician know. There are strategies to address these effects.

Try to avoid alcohol while on Depakote. Alcohol can worsen side effects such as drowsiness, dizziness, and cognitive impairment, and may interfere with the effectiveness of the medication. Both alcohol and Depakote can affect liver function, and combining them increases the risk of liver-related complications. Discuss alcohol use with your prescribing clinician.

Regular blood tests are essential when taking Depakote. Monitoring of serum valproate levels is required to ensure the medication remains within the therapeutic range. Your clinician will also typically monitor liver function (especially in the first six months of treatment) and complete blood counts, as Depakote can affect liver enzymes, platelet counts, and white blood cell counts. Your clinician will determine how frequently blood tests are needed based on your individual situation.

Do not stop Depakote abruptly without medical guidance. Stopping suddenly, particularly in individuals with seizure disorders, can trigger a rebound increase in seizure activity. In individuals using Depakote for bipolar disorder, abrupt discontinuation may increase the risk of mood episode recurrence. Always follow your psychiatric provider’s directions on when to stop taking medications or change dosages.

Depakote is associated with significant risks during pregnancy, including neural tube defects, cognitive impairment in children, and other congenital malformations. The FDA has assigned Depakote a specific warning regarding its use during pregnancy, and it is generally not recommended for use in pregnant individuals unless no adequate alternative is available. It’s important to discuss the risks and benefits of any medication for both the mother and baby with your healthcare provider.

While Depakote is not FDA-approved for anxiety, some clinicians may consider it off-label in specific contexts, particularly when anxiety co-occurs with bipolar disorder. If you are experiencing anxiety, speak with your clinician about evidence-based treatment options that may be more appropriate for your specific situation.

The cost of Depakote varies depending on whether you receive the generic or brand-name version and the formulation (DR vs. ER).

Generic divalproex sodium: As of publication date, oral delayed-release tablets (250 mg or 500 mg) range from approximately $8.56 to $14.46 for a 30-tablet supply.

Brand-name Depakote: As of publication date, brand-name tablets can range from approximately $218.76 to $700 or more for 100 tablets, depending on dosage strength.

If you have insurance, your out-of-pocket cost will depend on your supporting diagnosis and plan type (e.g., commercial, Medicare, Medicaid) and may include a copay or coinsurance.

They are closely related, though not exactly the same. Depakote (divalproex sodium) and valproic acid are two forms of the same active compound — valproate. Think of them like the same medicine packaged differently. Once either form is swallowed and absorbed, your body converts it into valproate, which is the active form of these related molecules.

The main practical difference is how your stomach handles them. Valproic acid is absorbed in the stomach and can cause nausea and upset stomach in many people. Depakote has a special coating that lets it pass through the stomach and dissolve in the intestine instead, which most people find much easier to tolerate.

Because both deliver the same compound to your bloodstream, they are used for the same conditions.

Depakote DR (delayed-release) and Depakote ER (extended-release) are different formulations of the same active ingredient. Depakote DR releases the medication after it passes through the stomach, reducing gastric irritation, but typically must be taken twice daily. Depakote ER releases the medication slowly over a longer period, resulting in more stable blood levels and typically once-daily dosing. The ER formulation may also be associated with fewer side effects such as nausea and tremor for some individuals, and allow a dosing schedule that minimizes the impact of drowsiness. Your clinician will recommend the formulation that best fits your treatment needs and lifestyle.

Both Depakote (divalproex sodium) and lithium carbonate are mood stabilizers used to treat bipolar disorder. Lithium has the strongest evidence for long-term mood stabilization and is one of the few psychiatric medications consistently associated with reduced suicide risk. Depakote may be preferred when rapid mood stabilization is needed or when lithium is not tolerated. Both require regular blood monitoring. The choice between them depends on your clinical history, tolerability, and treatment goals as determined by your clinician.

Depakene is the brand name for valproic acid, while Depakote is the brand name for divalproex sodium. Divalproex sodium was developed partly to improve gastrointestinal tolerability compared to valproic acid. Both release valproate as the active compound in the body, so their therapeutic effects are essentially the same. Depakote is more commonly prescribed in the United States.

Depakote (divalproex sodium) and Keppra (levetiracetam) are both anticonvulsants used to treat seizure disorders, but they work through different mechanisms and have distinct profiles. Depakote enhances GABA activity and modulates ion channels, while Keppra works by binding to a synaptic vesicle protein (SV2A) that modulates neurotransmitter release. Of the two, only Depakote has broader psychiatric indications, including bipolar disorder. Keppra is not indicated for the treatment of bipolar disorder or any other psychiatric condition, and may be associated with behavioral side effects such as irritability or mood changes.

Both Depakote (divalproex sodium) and Lamictal (lamotrigine) are mood stabilizers used in the treatment of bipolar disorder. Depakote is more commonly used for acute mania, while Lamictal is typically better suited for bipolar depression and long-term maintenance. Lamictal can be used off-label for treatment of unipolar depression. When prescribed together, careful dosing is critical, as Depakote significantly raises lamotrigine blood levels, increasing the risk of serious skin reactions (such as Stevens-Johnson syndrome). The selection of one over the other, or both, depends on your specific presentation and clinical history.

Depakote (divalproex sodium) is a mood stabilizer and anticonvulsant, while Seroquel (quetiapine) is a second-generation antipsychotic. Both are used in the treatment of bipolar disorder, but they act through different mechanisms. Seroquel is FDA-approved for acute manic and depressive episodes in bipolar disorder and as maintenance treatment. Depakote is primarily indicated for manic episodes. They may be used in combination in some treatment plans. The choice depends on your clinical presentation, side effect history, and treatment goals.